# A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

> **NCT06247995** · PHASE1,PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 58 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** [68Ga]Ga-NeoB
- **DRUG:** [177Lu]Lu-NeoB
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06247995
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-14
- **Primary completion:** 2031-09-09
- **Final completion:** 2031-09-09
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06247995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06247995, "A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06247995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*